Stocks Health care KZIA
NASDAQ · Health careKazia Therapeutics Ltd (KZIA)
Kazia Therapeutics Ltd reported revenue of A$42K in fiscal 2025, down 98.2% from a year earlier. It posted a net loss of A$20.7M. At June 30, 2025 it held A$4.3M in cash.
What Kazia Therapeutics Ltd does
Kazia Therapeutics Ltd is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker KZIA.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | A$42K | -A$20.7M | -A$0.04 | n/a |
| 2024 | A$2.3M | -A$26.8M | -A$0.10 | n/a |
| 2023 | A$0 | -A$20.5M | -A$0.11 | n/a |
| 2022 | A$0 | -A$25M | -A$0.19 | n/a |
| 2021 | A$15.2M | -A$8.4M | -A$0.07 | n/a |
| 2020 | n/a | -A$12.5M | -A$0.17 | n/a |
Latest SEC filings
What Kazia Therapeutics Ltd has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 22, 2026
- September 22, 2026
- September 22, 2026
- September 22, 2026
- September 22, 2026
- September 18, 2026
- September 18, 2026
- September 18, 2026
- September 18, 2026
- September 18, 2026
Questions about KZIA
What does Kazia Therapeutics Ltd do?
Kazia Therapeutics Ltd is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker KZIA.
Is Kazia Therapeutics Ltd profitable?
No. In fiscal 2025 it reported a net loss of A$20.7M on revenue of A$42K.
How much revenue does Kazia Therapeutics Ltd make?
In fiscal 2025 Kazia Therapeutics Ltd reported revenue of A$42K. That is 98.2% less than a year earlier.
When did Kazia Therapeutics Ltd last report?
Its newest filing of any kind is the securities offering prospectus from September 22, 2026.
Similar companies
Follow KZIA
Get an email when Kazia Therapeutics Ltd files with the SEC: results, executive changes, material agreements and annual reports.
Follow KZIA: get an email when it filesWhere the numbers come from
Financial figures are the values Kazia Therapeutics Ltd tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.